SGLT2 inhibitors and their role in reducing mortality among cancer patients with type 2 diabetes undergoing immune checkpoint inhibitor therapy.

Patients with type 2 diabetes mellitus (T2DM) and cancer undergoing immune checkpoint inhibitor (ICI) therapy face increased risks due to the convergence of metabolic, cardiovascular, and immune-related complications. Recent retrospective data suggest that sodium-glucose cotransporter-2 inhibitors (SGLT2i) may be associated with lower all-cause mortality in this population. These agents, initially developed for glycaemic control, are now recognised for their broader effects, including cardiovascular and renal protection, as well as anti-inflammatory and metabolic benefits. Importantly, these protective effects of SGLT2i have also been demonstrated in patients not treated with ICIs, as shown in recent experimental and clinical studies. Moreover, consistent evidence from large clinical trials indicates that SGLT2i confer significant reductions in mortality and hospitalisation when prescribed for heart failure or chronic kidney disease, even in patients without diabetes, thereby extending their benefits well beyond glycaemic control. Such properties may be particularly relevant in mitigating the cardiotoxic effects of ICIs, including myocarditis and arrhythmias. In addition, SGLT2i may influence tumour biology by altering glucose availability, improving insulin sensitivity, and modulating the tumour microenvironment, although these effects remain largely speculative and based on preliminary experimental evidence. While these hypotheses are supported by mechanistic plausibility and preliminary clinical observations, the retrospective design and limited sample size of the available data restrict definitive conclusions. Future prospective trials, with detailed cardiovascular monitoring, biomarker evaluation, and oncologic stratification, are needed to assess the true impact of SGLT2i in this setting. If confirmed, the use of SGLT2 inhibitors in patients with T2DM receiving ICIs may offer a novel therapeutic strategy that integrates cardiometabolic protection into oncologic care.